Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Next Previous
Trial Profile

A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gancotamab (Primary) ; Trastuzumab (Primary) ; Capecitabine; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HERMIONE
  • Sponsors Merrimack Pharmaceuticals

Most Recent Events

  • 05 Jan 2017 This trial was suspended in Austria, according to European Clinical Trials Database.
  • 21 Dec 2016 Status changed from recruiting to discontinued, according to a Merrimack Pharmaceuticals media release. The decision was based on an independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis which determined that continuing would be unlikely to demonstrate benefit over the comparator treatments. Patients currently enrolled in the trial may choose to continue on their assigned treatment based upon discussion with their study physician.
  • 11 Oct 2016 As per the trial design presented at 41st European Society for Medical Oncology Congress, enrollment is expected to be complete in 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top